Achievement of a Synergistic Adjuvant Effect on Arthritis Induction by Activation of Innate Immunity and Forcing the Immune Response Toward the Th1 Phenotype

Arthritis and Rheumatism

Volumn 50, Issue 5, 2004, Pages 1665-1676

  Hanyecz, Anita ^a,d   Berlo, Suzanne E ^b,d   Szántó, Sándor ^c,d   Broeren, Chris P M ^b   Mikecz, Katalin ^d   Glant, Tibor T ^d  

^a UNIVERSITY OF PÉCS   (Hungary)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF DEBRECEN   (Hungary)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; COLLAGEN; COLLAGEN TYPE 2; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; FREUND ADJUVANT; PROTEOGLYCAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; CATTLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOREACTIVITY; MALE; MORBIDITY; MOUSE; MOUSE STRAIN; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE; CATTLE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOPHENOTYPING; INCIDENCE; JOINTS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, SCID; QUATERNARY AMMONIUM COMPOUNDS; SEVERITY OF ILLNESS INDEX; SHEEP; SPECIES SPECIFICITY; SWINE; TH1 CELLS;

EID: 2342497178     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20180     Document Type: Article

References (40)

1. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen: an experimental model of arthritis. J Exp Med 1977;146:857-68.
2. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature 1980;282:666-8.
3. Glant TT, Mikecz K, Arzoumanian A, Poole AR. Proteoglycaninduced arthritis in BALB/c mice: clinical features and histopathology. Arthritis Rheum 1987;30:201-12.
4. Mikecz K, Glant TT, Poole AR. Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan. Arthritis Rheum 1987;30:306-18.
5. Glant TT, Buzas EI, Finnegan A, Negroiu G, Cs-Szabo G, Mikecz K. Critical role of glycosaminoglycan side chains of cartilage proteoglycan (aggrecan) in antigen recognition and presentation. J Immunol 1998;160:3812-9.
6. Glant Tr, Cs-Szabo G, Nagase H, Jacobs JJ, Mikecz K. Progressive polyarthritis induced in BALB/c mice by aggrecan from human osteoarthritic cartilage. Arthritis Rheum 1998;41:1007-18.
7. Glant TT, Bardos T, Vermes C, Chandrasekaran R, Valdez JC, Otto JM, et al. Variations in susceptibility to proteoglycan-induced arthritis and spondylitis among C3H substrains of mice: evidence of genetically acquired resistance to autoimmune disease. Arthritis Rheum 2001;44:682-92.
8. Glant TT, Finnegan A, Mikecz K. Proteoglycan-induced arthritis: immune regulation, cellular mechanisms and genetics. Crit Rev Immunol 2003;23:199-250.
9. Pearson CM. Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med 1956;91:95-101.
10. Anderton SM, van der Zee R, Prakken B, Noordzij A, van Eden W. Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis. J Exp Med 1995;181:943-52.
11. Wooley PH, Sud S, Whalen JD, Nasser S. Pristane-induced arthritis in mice. V. Susceptibility to pristane-induced arthritis is determined by the genetic regulation of the T cell repertoire. Arthritis Rheum 1998;41:2022-31.
12. Holmdahl R, Kvick C. Vaccination and genetic experiments demonstrate that adjuvant-oil-induced arthritis and homologous type II collagen-induced arthritis in the same rat strain are different diseases. Clin Exp Immunol 1992;88:96-100.
13. Lorentzen JC, Klareskog L. Susceptibility of DA rats to arthritis induced with adjuvant oil or rat collagen is determined by genes both within and outside the major histocompatibility complex. Scand J Immunol 1996;44:592-8.
14. Lorentzen JC. Identification of arthritogenic adjuvants of self and foreign origin. Scand J Immunol 1999;49:45-50.
15. Billiau A, Matthys P. Modes of action of Freund's adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 2001;70:849-60.
16. Glant TT, Mikecz K, Poole AR. Monoclonal antibodies to different protein-related epitopes of human articular cartilage proteoglycans. Biochem J 1986;234:31-41.
17. Antonopoulos CA, Axelsson I, Heinegard D, Gardell S. Extraction and purification of proteoglycans from various types of connective tissue. Biochim Biophys Acta 1974;338:108-19.
18. Bardos T, Kamath RV, Mikecz K, Glant TT. Anti-inflammatory and chondroprotective effect of TSG-6 (tumor necrosis factor-c-stimulated gene-6) in murine models of experimental arthritis. Am J Pathol 2001;159:1711-21.
19. Czipri M, Otto JM, Cs-Szabo G, Kamath RV, Vermes C, Fimeisz G, et al. Genetic rescue of chondrodysplasia and the perinatal lethal effect of cartilage link protein deficiency. J Biol Chem 2003;278:39214-23.
20. Miller EJ. Structural studies on cartilage collagen employing limited cleavage and solubilization with pepsin. Biochemistry 1972;11:4903-9.
21. Mikecz K, Brennan FR, Kim JH, Glant TT. Anti-CD44 treatment abrogates tissue edema and leukocyte infiltration in murine arthritis. Nat Med 1995;1:558-63.
22. Tsuruta LR, Quintilio W, Costa MH, Carmona-Ribeiro AM. Interactions between cationic liposomes and an antigenic protein: the physical chemistry of the immunoadjuvant action. J Lipid Res 1997;38:2003-11.
23. Bardos T, Mikecz K, Finnegan A, Zhang J, Glant TT. T and B cell recovery in arthritis adoptively transferred to SCID mice: antigen-specific activation is required for restoration of autopathogenic CD4+ Th1 cells in a syngeneic system. J Immunol 2002;168:6013-21.
24. Adarichev VA, Valdez JC, Bardos T, Finnegan A, Mikecz K, Glant TT. Combined autoimmune models of arthritis reveal shared and independent qualitative (binary) and quantitative trait loci. J Immunol 2003;170:2283-92.
25. Buzas EI, Hollo K, Garzo M, Lukacs K, Glant TT. Lack of evidence for molecular mimicry between 65kD heat shock protein (HSP) and cartilage proteoglycan (PG), which could provoke autoimmune responses and arthritis [abstract]. Arthritis Rheum 1995;38 Suppl 9:S295.
26. Gordon WC, Prager MD, Carroll MC. The enhancement of humoral and cellular immune responses by dimethyldioctadecylammonium bromide. Cell Immunol 1980;49:329-40.
27. Gall D. The adjuvant activity of aliphatic nitrogenous bases. Immunology 1966;11:369-86.
28. Stanfield JP, Gall D, Bracken PM. Single-dose antenatal tetanus immunisation. Lancet 1973;1:215-9.
29. Chambers JD, Thomas CR, Hobbs JR. Induction of specific transplantation tolerance in man by autoblast immunisation. Blut 1980;41:229-36.
30. Hilgers LA, Snippe H. DDA as an immunological adjuvant. Res Immunol 1992;143:494-503.
31. Snippe H, Johannesen L, Lizzio E, Merchant B. Variable expression of delayed hypersensitivity in different mouse strains using dimethyl dioctadecyl ammonium bromide as an adjuvant. Immunology 1980;39:399-405.
32. Baechtel FS, Prager MD. Interaction of antigens with dimethyldioctadecylammonium bromide, a chemically defined biological response modifier. Cancer Res 1982;42:4959-63.
33. Kraaijeveld CA, la Riviere G, Benaissa-Trouw BJ, Jansen J, Harmsen T, Snippe H. Effect of the adjuvant dimethyl dioctadecyl ammonium bromide on the humoral and cellular immune responses to encephalomyocarditis virus. Antiviral Res 1983;3:137-49.
34. Hilgers LA, Snippe H, Jansze M, Willers JM. Synthetic sulpholipopolysaccharides: novel adjuvants for humoral immune responses. Immunology 1987;60:141-6.
35. Katz D, Lehrer S, Galan O, Lachmi BE, Cohen S. Adjuvant effects of dimethyl dioctadecyl ammonium bromide, complete Freund's adjuvant and aluminium hydroxide on neutralizing antibody, antibody-isotype and delayed-type hypersensitivity responses to Semliki Forest virus in mice. FEMS Microbiol Immunol 1991;3:305-20.
36. Leal IS, Smedegard B, Andersen P, Appelberg R. Failure to induce enhanced protection against tuberculosis by increasing T-cell-dependent interferon-γ generation. Immunology 2001;104: 157-61.
37. Klinguer-Hamour C, Libon C, Plotnicky-Gilquin H, Bussat MC, Revy L, Nguyen T, et al. DDA adjuvant induces a mixed Th1/Th2 immune response when associated with BBG2Na, a respiratory syncytial virus potential vaccine. Vaccine 2002;20:2743-51.
38. Mia MY, Zhang L, Hossain A, Zheng CL, Tokunaga O, Kohashi O. Dimethyl dioctadecyl ammonium bromide (DDA)-induced arthritis in rats: a model of experimental arthritis. J Autoimmun 2000;14:303-10.
39. Swanborg RH. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol Rev 2001;184:129-135.
40. Hart BA, Vervoordeldonk M, Heeney JL, Tak PP. Gene therapy in nonhuman primate models of human autoimmune disease. Gene Ther 2003;10:890-901.